Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Current Leases (2018 - 2025)

Cytosorbents' Current Leases history spans 8 years, with the latest figure at $541000.0 for Q4 2025.

  • Quarterly results put Current Leases at $541000.0 for Q4 2025, up 19.43% from a year ago — trailing twelve months through Dec 2025 was $541000.0 (up 19.43% YoY), and the annual figure for FY2025 was $541000.0, up 19.43%.
  • Current Leases for Q4 2025 was $541000.0 at Cytosorbents, up from $518000.0 in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $570566.0 in Q4 2021 to a low of $108939.0 in Q4 2022.
  • The 5-year median for Current Leases is $414464.0 (2022), against an average of $368718.6.
  • The sharpest move saw Current Leases plummeted 80.91% in 2022, then soared 268.59% in 2024.
  • Year by year, Current Leases stood at $570566.0 in 2021, then plummeted by 80.91% to $108939.0 in 2022, then soared by 242.98% to $373636.0 in 2023, then increased by 21.24% to $453000.0 in 2024, then rose by 19.43% to $541000.0 in 2025.
  • According to Business Quant data, Current Leases over the past three periods came in at $541000.0, $518000.0, and $495000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.